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Abstract 
Objective: To evaluate the hypoglycemic effect of Avartaki Churna (Cassia auriculata Linn.) in experimental 
animals. Materials and Methods: Avartaki Churna was prepared by the standard procedure of Churna Kalpana. 
Hyperglycemia was induced to create an equivalent to the diabetic state by giving streptozotocin (STZ) solution 
(intra-peritoneal [i.p.]) 35 mg/kg.  After assessment of hyperglycemia as an approximate induction of diabetes, 
Group IV animals were treated with 300 mg/kg of Avartaki Churna. For treatment comparison, Group III animals 
were treated with a standard hypoglycemic drug, glibenclamide 1 mg/kg. Blood sugar level was assessed by 
glucometer on the 7th, 14th, 21st  and 28th   day. Results: Avartaki Churna produced a significantly reduction of 
fasting blood glucose with various doses in STZ-induced diabetic rats. In a 4-week study, Avartaki Churna 
produced a significant reduction in blood glucose compared to glibenclamide. Conclusion: Avartaki Churna and 
glibenclamide significantly reduced blood sugar level. The results were more significant with successive days in 
this in vivo comparative study. 
 
Keywords : Avartaki Churna, Prameha, Streptozotocin  
*Corresponding Author: 
KRC Reddy 
Department of Rasa Shastra 
Faculty of Ayurveda, IMS, BHU 
Varanasi. U.P. 221005 
Email: drkrcreddybhu@yahoo.co.in 
Ph.No: +91-9415813533 
Introduction 
           In Ayurveda Prameha/Madhumeha can be 
considered as Diabetes Mellitus by different 
perspectives based on clinical symptoms and attempts 
have been made by Ayurvedic physicians and 
researchers to treat these two entities by using classical 
formulations mentioned in Prameha Chikitsa.(1) The 
first and most elaborated description of Avartaki in a 
classical text is available in Kaiyadeva Nighantu, where 
it’s Pramehaghna/ Madhumehaghna action through 
different botanical parts of plant has been mentioned. 
Kaiyadeva Nighantu is written by Kaiyadeva in 15th 
century. According to Kaiyadeva Nighantu, the flower 
has Pramehashamana property. The tender fruits have 
been indicated as Sarvapramehahara. The seeds are said 
to be Madhumehaghna, and the root is used as 
Pramehaghna.(2) 
          Diabetes mellitus, a major lifestyle disease is 
undoubtedly the most challenging public health 
problem of 21st century with a worldwide prevalence 
of 387 million (8.3%) and predicted to be 592 million 
by 2035. 77% of people with diabetes live in low- and 
middle-income countries. India, once known as the 
‘diabetes capital of the world’ was home to 61.3 million 
patients with T2DM in 2011 with predictions of 101.2 
million diabetics by 2030. India is second only to China 
which is home to 92.3 million diabetics.(3)(4) 
 
Materials and methods 
Selection and Collection of Plant Materials:  
  Avartaki (whole plant) was collected from the 
peripheral regions of Satara district, Maharashtra, India. 
The collected sample was pharmacogonostically 
identified and confirmed in Department of Dravyaguna, 
Faculty of Ayurveda, IMS, Banaras Hindu University, 
Varanasi.  
 
Churna Preparation 
 The collected plant material of Avartaki Churna 
were cleaned and dried in the sunlight. The dried plant 
material was then ground into a fine powder using a 
mechanical pulverizer in Ayurvedic Pharmacy, Banaras 
Hindu University, Varanasi, India. This sample was 
used for anti-diabetic study. 
 
Chemicals  
 Streptozotocin was sponsored by Department of 
Rasa-Shastra, Faculty of Ayurveda, IMS, BHU, 
Varanasi, which was purchased from Himedia 
Laboratories Pvt. Ltd. Dindori, Nashik, India. Batch 
number was 0000222052, manufacturing date was 
November 2014 and Expiry date is February 2017. 
Glibenclamide was purchased from Emcure SANOFI, 
trade name Daonil (Manufacturing date April 2015 and 
Expiry date 2016) in India, for use as the standard anti-
diabetic agent.  
 
Animals  
 24 Charles Foster albino rats of either sex 
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weighing between 180 ± 30 g were used for the 
experimental study. The animals were obtained from the 
Central Animal House, Institute of Medical Sciences, 
Banaras Hindu University, Varanasi. The animals were 
freely allowed to eat pellet chow (Amrut Laboratory 
Animal Feed, Pranav Agro Industries Limited, Sangali) 
and ad libitum water during the study periods. 
Principles of laboratory animal care as per NIH 
guidelines were always followed and prior approval of 
Institutional Animal Ethical Committee (Reg. 
No.Dean/2014-15/EC/1057) of BHU was obtained 
before commencing experiments.(5)(6) 
 
Experimental Protocol 
The experimental study was conducted at the 
Department of Pharmacology, IMS, BHU. 24 animals 
were divided into four groups and were kept under 
standard laboratory condition during the study. The 
groups were named normal control (NC) (Group I), 
diabetic control (DC) non-treated (Group II), diabetic 
standard group (GB) (Group III) and the group of 
Avartaki Churna (AV300) (Group IV)  
 Before induction of hyperglycemia as an 
approximate induction of DM, the rats were kept fasting 
from all food; only water was given. Immediately prior 
to injection, STZ was dissolved in 50 mg of sodium 
citrate buffer (pH 4.5) to a final concentration of 1 mg/
ml. The STZ solution was freshly prepared for each rat 
and was injected within 5 min after being dissolved. 
Hyperglycemia was induced (in-Group II to IV) by STZ 
solution intra-peritoneal (i.p.) using a dose of 35 mg/kg 
through insulin syringes. After 72 h blood sugar level 
was measured by Optimum Xceed glucometer (Abbott). 
For investigation of blood glucose, blood of rats was 
drawn through a tail central vein. Hyperglycemia was 
confirmed by the elevated glucose level in the blood by 
glucometer, determined after 72 h.(7) On the 7th day 
after confirmation of hyperglycemia, animals of Group 
IV were treated with Avartaki Churna. Animals of 
Group III were treated with hypoglycemic drug 
glibenclamide 1 mg/kg. Glibenclamide stimulates the 
pancreatic beta cells of the pancreas and increasing the 
sensitivity of the peripheral tissue to insulin. Data of 
blood sugar was collected every 7th day of duration for 
4 weeks and compared among groups.  
 
Dose Schedule 
 24 Charles Foster rats were divided into four 
groups, namely NC (Group I), DC (Group II), standard 
group treated with glibenclamide in dose of 1 mg/kg 
body weight (Group III) and treated group with 
Avartaki Churna (Group IV) in the dose of 300 mg/kg 
body weight. The test drug Avartaki Churna and 
standard drug glibenclamide were administered 
according to the body weight of the animal by oral route 
with the help of intragastric tube.  
 
Statistical Analysis 
 Statistical analysis of data was performed using 
SPSS 16.0 and one-way analysis of variance. Results 
were expressed as mean ± standard deviation from six 
rats in each group. P < 0.05 was considered statistically 
significant and <0.001 were considered highly 
significant in the results of this study.  
 
Results 
 The base line value in all four groups of albino 
rats showed that the fasting blood glucose (FBG) levels 
were within normal limits. The first task was to create 
an experimental model of hyperglycemia. A single dose 
(35 mg/kg) of STZ was administered to Groups II-IV, 
leaving Group I as an NC. Hyperglycemia was 
significantly induced compared to NC FBG after 72 h 
and was confirmed on the 7th day following STZ 
administration [Figure 1].  
                       
 
Figure 1: The effect on fasting blood sugar  in 
streptozotocin-induced albino rats, where values are 
given as mean ± standard deviation (n = 6 in each 
group). Values are statistically significant at P < 0.05,  
P < 0.001 compared with normal control group. 
              
  The second task was to evaluate dose-dependence 
on reduction in blood glucose of experimentally-
hyperglycemic rats in our diabetic model. The stock 
solution was prepared freshly by adequate quantity of 
distilled water with the Avartaki Churna was given at 
the dose of 300 mg/kg, to each of six rats in Group IV. 
Results are shown in Table 1, and demonstrated a dose-
dependent reduction, with 300 mg/kg showing the 
greatest reduction in blood glucose level. Avartaki 
Churna produced a maximum reduction of blood 
glucose of % (P < 0.001) 1 h with dose of 300 mg/kg.
[Figure 2].  
                          
 
Figure 2: The effect of dose of Avartak i Churna on 
fasting blood sugar in streptozotocin-induced albino 
rats, where values are given as mean ± standard 
deviation (n = 6 in each group). Values are statistically 
significant at P < 0.05, P < 0.001 compared with 
diabetic control group. 
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 The next task was to compare a dose of 
Avartaki Churna with a standard anti-diabetic drug, 
glibenclamide. In a 4-week study, Avartaki Churna 
produced a statistically highly significant reduction in 
blood glucose on day 7, compared to glibenclamide, as 
shown in Table 1. Glibenclamide (1 mg/kg) produced a 
maximum reduction of FBG 63% (1 h, P < 0.001) 
compared to DC Group II.[Figure 3]. 
 
 
Figure 3: The effect of dose of Avartak i Churna and 
glibenclamide on fasting blood sugar in streptozotocin-
induced albino rats, where values are given as mean ± 
standard deviation (n = 6 in each group). Values are 
statistically significant at P < 0.05, P < 0.001 compared 
with control group. 
 
The results indicate a prolonged action in a 
reduction in blood glucose by Avartaki Churna and are 
probably mediated through enhanced secretion of 
insulin from β-cells of Langerhans or through an extra-
pancreatic mechanism. In the treated group for 4 weeks, 
significant reduction of FBG level was observed.  
Mean and SD of sugar of normal group and 
various treatment groups on day 0, 7, 14, 21, and 28 
was determined and show in Table 1. Mean sugar in 
NC group was much smaller as compare to other 
groups. Mean sugar level decreased successively on 
different days. The inter group comparison was 
statistically highly significant on each 7th day 
observation. Post-hoc test for pair wise group 
comparison was also applied, and pairs were found 
statistically significant were shown in Table 1. 
 
Discussion 
           Avartaki (Cassia auriculata Linn.) is a herbal 
drug mentioned elaborately in Kaiyadeva Nighantu with 
its Pramehaghna/Madhumehaghna properties. The same 
plant have also been studied in modern science and 
showed a significant reduction in blood glucose level in 
DM animal models by various mechanisms. Gupta et al. 
(2010) found Cassia auriculata Linn.leaf extract has 
insulinogenic action in streptozotocin-induced diabetic 
rats.(8) Latha et al. (2003) found Cassia auriculata Linn. 
flower extract suppresses enhanced gluconeogenesis 
and enhances utilization of glucose through increased 
glycolysis in streptozotocin-induced diabetic rats.(9) 
Abesundara et al. (2004) showed that Cassia auriculata 
Linn. flower extract exerts a strong antihyperglycemic 
effect in rats comparable to the therapeutic drug 
acarbose.(10) Venkatachalam et al. found that aqueous 
extract of flowers of Cassia auriculata Linn. has PTP-
1B inhibitory activity in Alloxan induced diabetic rats.
(11) Brahmachari et al. showed that aqueous extract of 
whole plant of Casssia auriculata Linn.has 
hypoglycemic effect in STZ-induced diabetic rats.(12)   
            It is believed that the basis of the chemical 
constitution of different herbal drugs and various 
medicinal/plant extracts contain active flavonoids, 
alkaloids, phenolic compounds, terpenoids, saponins, 
and phytosterol type chemical constituents that are 
effective in the management of diabetic complications. 
This effect might be attributed to the amelioration of 
persistent hyperglycemia, oxidative stress, and 
modulations of the various metabolic pathway involved 
in the pathogenesis of diabetic complications.(13) The 
plant Avartaki (Cassia auriculata Linn) has number of 
phytochemicals in its various extracts of different 
botanical parts.(14)  
 In our study, Avartaki Churna showed a significant 
decrease in blood sugar level both compared to a 
Table 1: Effect of Avar taki Churna on blood sugar  level (mg/dl) 
 
Values are given as mean±SD (n=6 in each group). Values are statistically significant at *P<0.05, ***P<0.001 
compared with control group. NC: Normal control, DC: Diabetic control, GB: diabetic standard group 
(Glibenclamide treated), AV300: Avartaki Churna in 300 mg dose,  SD: Standard deviation. 
Groups Day 0 Day 7 Day 14 Day 21 Day 28 
NC 106.50 ± 4.46 112.67 ± 5.164 114.0 ± 3.79 113.0 ±  4.14 103.67 ± 4.63 
DC 335.0 ± 23.62 333.33 ± 17.51 338.0 ± 10.04 324.33 ± 11.82 330.0 ± 16.44 
GB 326.67 ± 17.28 231.0 ± 26.79 175.50 ± 19.26 150.0 ±  10.19 119.67 ± 7.52 
AV300 326.83 ± 21.86 188.67 ± 6.25 155.50 ± 15.57 142.33 ± 9.00 140.17 ± 4.49 
One way 
Anova 
F=220.51 
P=0.000 
F=186.47 
P= 0.000 
F= 317.67 
P= 0.000 
F= 645.74 
P= 0.000 
F= 724.23 
P= 0.000 
Post Hoc (I II), (I III), 
(I IV) 
(I II), (I III), 
(I IV), (II III), (II 
IV), (III IV) 
  
(I II), (I III), 
(I IV), (II III), (II 
IV), (III II) 
  
(I II),(I III), 
(I IV), (II III), (II 
IV), (III II) 
  
(I II), (I IV), (II 
III), (II IV), (III 
II), (III IV) 
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diabetic non-treated control group and to a group treated 
with a standard anti-diabetic drug, glibenclamide in an 
animal model that replicated hyperglycemia. This study 
attempts to show that the mode of action of Avartaki 
Churna may be similar to the mode of action of 
glibenclamide, i.e. by stimulating the pancreatic beta 
cells of the pancreas and increasing the sensitivity of the 
peripheral tissue to insulin. STZ causes selective 
destruction of insulin secreting beta cells and raised 
blood sugar level in animals.(15) STZ, N-
(methylnitrocarbon)-D-glucosamine is a potent 
methylatning agent for DNA and acts as nitric oxide 
donor in pancreatic β-cell and thus β-cells are more 
sensitive to damage by nitric oxide and free radical 
scavenging enzyme.(16) 
 
Conclusion:   
 Avartaki Churna significantly decreases blood 
sugar level in experimental animals induced by STZ. 
Avartaki Churna reduced blood sugar level gradually. 
The results suggest a protective role of Avartaki Churna 
in STZ-induced hyperglycemia. 
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